生物技术公司Zymeworks Inc宣布，其创新药物Ziihera若能在美国、欧洲、日本及中国四大关键市场成功获得监管批准，公司将有望触发总计最高达4.4亿美元的里程碑付款。这一潜在收益凸显了Ziihera的全球商业化价值，也反映出国际监管机构对该疗法前景的认可。随着Ziihera在主要医药市场的审批进程推进，这些阶段性付款将为企业研发管线注入持续动力。
生物技术公司Zymeworks Inc宣布，其创新药物Ziihera若能在美国、欧洲、日本及中国四大关键市场成功获得监管批准，公司将有望触发总计最高达4.4亿美元的里程碑付款。这一潜在收益凸显了Ziihera的全球商业化价值，也反映出国际监管机构对该疗法前景的认可。随着Ziihera在主要医药市场的审批进程推进，这些阶段性付款将为企业研发管线注入持续动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.